5 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 71, n° 1
pages 161-169 (juillet 2014)
Doi : 10.1016/j.jaad.2014.02.035
accepted : 24 February 2014

Ipilimumab in patients with cancer and the management of dermatologic adverse events

Mario E. Lacouture, MD a, b, , Jedd D. Wolchok, MD, PhD a, b, c, Gil Yosipovitch, MD d, Katharina C. Kähler, MD e, Klaus J. Busam, MD a, Axel Hauschild, MD e
a Memorial Sloan Kettering Cancer Center, New York, New York 
b Weill-Cornell Medical College, New York, New York 
c Ludwig Institute for Cancer Research, New York, New York 
d Departments of Dermatology, Neurobiology and Anatomy, and Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina 
e Department of Dermatology, University of Kiel, Kiel, Germany 

Correspondence to: Mario E. Lacouture, MD, Memorial Sloan Kettering Cancer Center, Suite 228, 160 E 53 St, New York, NY 10022.

Ipilimumab is a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumor T-cell responses. Phase III studies have demonstrated survival benefit in both previously treated and treatment-naïve patients with metastatic melanoma. In clinical trials, adverse events (AEs) related to treatment with ipilimumab were mostly grade 1/2 (as per Common Terminology Criteria for AEs, Version 4.02), and mostly reversible with appropriate management. Distinct immune-related AEs that may reflect the mechanism of action of ipilimumab have been identified, and occur commonly in the skin, typically presenting as a maculopapular rash, which can be accompanied by pruritus, pruritus with no skin lesions, alopecia, and vitiligo. Histologic analyses have revealed epidermal spongiosis, and perivascular CD4+ T-cell infiltrates with some eosinophils in areas of rash. Timely implementation of toxicity-specific treatment guidelines that emphasize vigilance and early intervention allows mitigation of dermatologic AEs. Adherence to guidelines is necessary to maintain quality of life, ensure consistent dosing, and obtain the best possible clinical outcome.

The full text of this article is available in PDF format.

Key words : adverse event management, dermatologic, immune-related, ipilimumab, melanoma, pruritus, rash, vitiligo

Abbreviations used : AE, CTLA, GI, irAE

 The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. The authors also wish to acknowledge StemScientific, funded by Bristol-Myers Squibb, for providing writing and editorial support. Neither Bristol-Myers Squibb nor StemScientific influenced the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.
 Disclosure: Dr Lacouture received honoraria for advisory board membership and consultancy with Bristol-Myers Squibb and consultancy for Advancell, Amgen, Bayer, Berg, Galderma, Genentech, GSK, Helsinn, Merck, Novartis, Novocure, OSI, and Pfizer. Dr Wolchok received honoraria for consultancy for AstraZeneca, Bristol-Myers Squibb, and Merck. Dr Kähler received honoraria for advisory board membership, consultancy, and as a speaker. Dr Hauschild received honoraria for advisory board membership and consultancy as well as payments for lectures including services on speakers' bureaus and research funding from the following companies: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eisai, GSK, IGEA, Lilly, MelaSciences, Merck Serono, MSD/Merck, Novartis, Oncosec, and Roche Pharma. Drs Yosipovitch and Busam have no conflicts of interest to declare.
 Reprints not available from the authors.

© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline